Quantitative in vitro to in vivo extrapolation of tissues toxicity.

Predicting repeated-dosing in vivo drug toxicity from in vitro testing and omics data gathering requires significant support in bioinformatics, mathematical modeling and statistics. We present here the major aspects of the work devoted within the framework of the European integrated Predict-IV to pharmacokinetic modeling of in vitro experiments, physiologically based pharmacokinetic (PBPK) modeling, mechanistic models of toxicity for the kidney and brain, large scale dose-response analyses methods and biomarker discovery tools. All of those methods have been applied to various extent to the drug datasets developed by the project's partners. Our approach is rather generic and could be adapted to other drugs or drug candidates. It marks a successful integration of the work of the different teams toward a common goal of predictive quantitative in vitro to in vivo extrapolation.

[1]  Bas J Blaauboer,et al.  Biokinetic Modeling and in Vitro–in Vivo Extrapolations , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[2]  Weihsueh A. Chiu,et al.  Addressing Human Variability in Next-Generation Human Health Risk Assessments of Environmental Chemicals , 2012, Environmental health perspectives.

[3]  Eric Leclerc,et al.  First pass intestinal and liver metabolism of paracetamol in a microfluidic platform coupled with a mathematical modeling as a means of evaluating ADME processes in humans , 2014, Biotechnology and bioengineering.

[4]  Kairui Feng,et al.  The Simcyp Population Based Simulator: Architecture, Implementation, and Quality Assurance , 2013, In Silico Pharmacology.

[5]  Peter J H Webborn,et al.  Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes , 2008, Drug Metabolism and Disposition.

[6]  Hans V Westerhoff,et al.  Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathione-depletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[7]  Frédéric Y. Bois,et al.  Population-Based Pharmacokinetic Modeling and Simulation , 2012 .

[8]  George Loizou,et al.  Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[9]  A. Kopp-Schneider,et al.  Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[10]  Jérémy Hamon,et al.  Extrapolating In Vitro Results to Predict Human Toxicity , 2014 .

[11]  D. Maahs,et al.  Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  Simon Thomas,et al.  Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. , 2008, Journal of pharmaceutical sciences.

[13]  Melvin E Andersen,et al.  Phase I to II cross-induction of xenobiotic metabolizing enzymes: a feedforward control mechanism for potential hormetic responses. , 2009, Toxicology and applied pharmacology.

[14]  M. Jamei,et al.  A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine , 2013, Clinical Pharmacokinetics.

[15]  Frédéric Y. Bois,et al.  GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models , 2009, Bioinform..

[16]  Jon A Arnot,et al.  Application of mass balance models and the chemical activity concept to facilitate the use of in vitro toxicity data for risk assessment. , 2014, Environmental science & technology.

[17]  Valérie Zuang,et al.  Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 , 2011, Archives of Toxicology.

[18]  Krishna Prasad,et al.  Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium , 2010, Nature Biotechnology.

[19]  R. Dhir,et al.  Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography , 2012, BMC Medicine.

[20]  Bas J Blaauboer,et al.  Dose metric considerations in in vitro assays to improve quantitative in vitro-in vivo dose extrapolations. , 2015, Toxicology.

[21]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[22]  A. Guillouzo,et al.  Running title page Running title : Functional stability of CYP P 450 enzymes in HepaRG cells , 2009 .

[23]  Paul Jennings,et al.  Integration of Omics Data and Systems Biology Modeling: Effect of Cyclosporine A on the Nrf2 Pathway in Human Renal Kidneys Cells , 2013, 1312.4744.

[24]  B. Mayer,et al.  Systems biology: building a useful model from multiple markers and profiles. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  H. Westerhoff,et al.  Systems biology tools for toxicology , 2012, Archives of Toxicology.

[26]  R. Kim,et al.  Transporters and drug therapy: Implications for drug disposition and disease , 2005, Clinical pharmacology and therapeutics.

[27]  Bas J Blaauboer,et al.  Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. , 2013, Journal of proteomics.

[28]  Lu Gaohua,et al.  Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM) , 2013 .

[29]  Eric Leclerc,et al.  Integration of pharmacokinetic and NRF2 system biology models to describe reactive oxygen species production and subsequent glutathione depletion in liver microfluidic biochips after flutamide exposure. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.

[30]  Andreas Heinzel,et al.  Data Graphs for Linking Clinical Phenotype and Molecular Feature Space , 2012 .

[31]  Malcolm Rowland,et al.  Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. , 2005, Journal of pharmaceutical sciences.

[32]  O. Pelkonen,et al.  In vitro–in vivo extrapolation of hepatic clearance: Biological tools, scaling factors, model assumptions and correct concentrations , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[33]  Andreas Heinzel,et al.  Using Information Content for Expanding Human Protein Coding Gene Interaction Networks , 2013 .

[34]  H. Yamada,et al.  Identification of genomic biomarkers for concurrent diagnosis of drug-induced renal tubular injury using a large-scale toxicogenomics database. , 2009, Toxicology.

[35]  Robert J. Bauer,et al.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples , 2007, The AAPS Journal.

[36]  S. Jung,et al.  Recent technological updates and clinical applications of induced pluripotent stem cells , 2014, The Korean journal of internal medicine.

[37]  Yasuyuki Sakai,et al.  Kinetic modelling of in vitro cell-based assays to characterize non-specific bindings and ADME processes in a static and a perfused fluidic system. , 2011, Toxicology letters.

[38]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[39]  R. Day,et al.  Clinical Pharmacokinetics of Metformin , 2011, Clinical pharmacokinetics.

[40]  A. Kopp-Schneider,et al.  Stochastic time‐concentration activity models for cytotoxicity in 3D brain cell cultures , 2013, Theoretical Biology and Medical Modelling.

[41]  Kannan Krishnan,et al.  Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms , 2012, Journal of toxicology.

[42]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[43]  Harvey J Clewell,et al.  PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. , 2014, Regulatory toxicology and pharmacology : RTP.